Quantcast
⋮
0
0
Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant
← $
X
Sharing:
Title:
URL:
Copy Share URL